Drugs / IMP4297
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT05390944 | Jun → Aug 2022 | cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05391048 | Jun → Jul 2022 | cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT05262842 | Mar 2022 → Apr 2024 | cancer of unknown primary site | Shanghai Junshi Bioscience Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 1 | NCT05109832 | Oct → Dec 2021 | cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04584515 | Nov 2020 → Mar 2021 | cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04351165 | Oct 2020 → Feb 2021 | neoplasm | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04057729 | Jul → Sep 2019 | cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03508011 | Aug 2017 → Dec 2020 | breast cancer, ovarian cancer, prostate cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03507543 | Feb 2017 → Sep 2020 | breast cancer, ovarian cancer, primary peritoneal carcinoma, prostate cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04434482 | Aug 2020 → Apr 2024 | small cell lung carcinoma | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07120451 | Oct 2025 → Oct 2026 expected | ovarian carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06617923 | Feb 2025 → Oct 2027 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 2 | NCT04089189 | Oct 2019 → Jun 2023 | ovarian cancer | Impact Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04169997 | Dec 2019 → Mar 2023 overdue | ovarian cancer | Impact Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04822961 Comparator | Dec 2021 → May 2024 | castration-resistant prostate carcinoma | Impact Therapeutics, Inc. | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP4297 | “Senaparib (IMP4297) 20 mg” NCT04822961 ↗ |
| Known as | Senaparib | “Effect of a strong CYP3A4 inhibitor and inducer on the pharmacokinetics of senaparib (IMP4297) in healthy volunteers: A drug-drug interaction study.” PMID 36458825 ↗ Jan 20238“Senaparib is a PARP inhibitor that demonstrated antitumor activity in patients with solid tumors, including ovarian cancer, in phase 1 studies.” PMID 38750351 ↗ May 2024 “Senaparib is a novel, selective poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies.” PMID 36718624 ↗ Jan 2023 “Effect of Food on the Pharmacokinetics of Senaparib (IMP4297) in Healthy Chinese Subjects.” PMID 36239914 ↗ Oct 2022 “IMP4297(senaparib) and temozolomide” NCT04434482 ↗ “senaparib (PARP Inhibitor)” NCT05262842 ↗ |
| Action | Inhibit | “Senaparib is a novel, selective poly(ADP-ribose) polymerase-1/2 inhibitor with strong antitumor activity in preclinical studies.” PMID 36718624 ↗ Jan 2023 |
| Route | Oral | “Patients received one dose of oral senaparib and, if no dose-limiting toxicity occurred within 7 days, they received senaparib once daily in 3-week cycles.” PMID 36718624 ↗ Jan 2023 |
| Target | PARP1 | “PARP1/2 Inhibitor” PMID 37338150 ↗ Dec 2023 |